Zytiga (abiraterone), approved since 2011 for use in prostate cancer, is its biggest selling cancer drug, and saw sales jump 45.5% compared with last year’s Q4 to $755 million. Full-year sales ...

Draft guidance from the cost effectiveness watchdog says Zytiga (abiraterone) should not be used in prostate cancer which has spread in men whose first treatment has failed, have no or mild ...

A new Federal Trade Commission (FTC) report found that the three largest Pharmacy Benefit Managers (PBMs) have taken in large ...

There are warnings on all of them. They still have the warnings… [with abiraterone (Zytiga)]. I have been decreasing the prednisone even more. I even remember one of the earlier studies that used 4 mg ...

NICE is unable to make a recommendation about the use in the NHS of niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer in adults. This is ...

Abiraterone acetate (CB7630), a pregnenolone analog, is an orally administered small molecule that irreversibly inhibits a rate-limiting enzyme in androgen biosysnthesis, CYP17, and blocks the ...

To the best of our knowledge, this is the first study aimed at identifying factors predicting primary NHA resistance. In our experience of everyday clinical practice in an unselected CRPC ...

The PEACE-1 trial (NCT01957436) revealed that adding radiotherapy to standard of care (SOC) and abiraterone significantly improved radiographic progression-free survival (rPFS) in patients with ...

NICE is unable to make a recommendation about the use in the NHS of niraparib (Zejula) with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer in adults. This ...

Resources on the symptoms, diagnosis, and treatment of prostate cancer.

This video segment explores how to choose between the original brand, generic, and micronized versions of abiraterone, considering factors like efficacy, cost, patient preference, and clinical context ...